Silence Therapeutics

• NCT05537571

  Phase 2, Completed, 180 people, 13 Sept 2022

• Hansoh Pharmaceutical

  Licence, 15 Oct 2021

Sources: www1.hkexnews.hk

• Comprehensive benchmarking of somatic mutation detection by the SMaHT Network

  Grants or research support, 15 Oct 2026

• Association of Life's Essential 8 With Clonal Hematopoiesis and Coronary Artery Disease

  Grants or research support, 15 Oct 2026

• Lipoprotein(a)-dependent cardiovascular risk in different populations: are thresholds the same?

  Consulting or advice, Fees or honoraria, Grants or research support, 10 Oct 2026

• Predictive Utility of Coronary Artery Calcium Score Added to the PREVENT Atherosclerotic Cardiovascular Disease Equations

  Fees or honoraria, Board or leadership role, 6 Oct 2026

• Derivation of a blood count-based machine learning model to prioritise sequencing for high-risk clonal haematopoiesis: a retrospective cohort study

  Grants or research support, 22 Sept 2026

• Type 1 interferon perturbates clonal competition by reshaping human blood development

  Consulting or advice, 15 Sept 2026

• Gaps in lipid management among high-risk patients without prior MI or stroke: the VESALIUS-REAL global study

  Consulting or advice, Fees or honoraria, Grants or research support, 3 Sept 2026

• Hepatic Steatosis and Cardiovascular Risk in Obesity: A 10-Year Follow-Up Study From Childhood Into Young Adulthood

  Consulting or advice, Fees or honoraria, Grants or research support, 1 Sept 2026

• Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a)

  Consulting or advice, Fees or honoraria, Grants or research support, 31 Aug 2026

• Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study

  Fees or honoraria, 28 Aug 2026

• Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

  Fees or honoraria, Grants or research support, Board or leadership role, 28 Aug 2026

• Coronary Inflammation Is Associated With Plaque Progression in Men With HIV

  Consulting or advice, Fees or honoraria, 26 Aug 2026

• Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial

  Consulting or advice, Grants or research support, 18 Aug 2026

• Implications of the 2026 Versus 2018 ACC/AHA Multisociety Dyslipidemia Guidelines on the Clinical Care of U.S. Adults

  Consulting or advice, Fees or honoraria, 29 Jul 2026

• Real-world efficacy of inclisiran: data from a tertiary lipid clinic

  Consulting or advice, Fees or honoraria, Grants or research support, 1 Apr 2026

• Genomic, phenomic and geographic associations of leukocyte telomere length in the United States

  Grants or research support, 27 Mar 2026

Sources: pubmed.ncbi.nlm.nih.gov